Durvalumab plus chemo before surgery for high-risk bile duct cancer
Treatments studied
Part of Cancer clinical trials.
This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy (gemcitabine and cisplatin) before surgery helps people with a high-risk type of bile duct cancer live longer. If you qualify, you would receive the drug combination before your planned surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of bile duct cancer called intrahepatic cholangiocarcinoma (iCCA) that can be removed with surgery.
- Your cancer has at least one high-risk feature, like being larger than 5 cm, having more than one tumor, growing into blood vessels, or having a high CA 19-9 blood test level.
- You have not had any previous treatment for this cancer.
- Your health is good enough for surgery and you can do most daily activities on your own.
- You are 18 years or older, weigh more than 66 pounds (30 kg), and have adequate kidney, liver, and blood cell counts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs (durvalumab, cisplatin, and gemcitabine, with or without futibatinib) given before surgery to treat intrahepatic cholangiocarcinoma—a rare cancer of the bile ducts inside the liver. The goal is to shrink the tumor and improve outcomes after surgery.
This trial tests giving durvalumab (an immunotherapy drug) together with chemotherapy before surgery for bile duct or gallbladder cancer. The goal is to see if this combination shrinks tumors and improves outcomes for patients whose cancer is considered high-risk but still removable.
This trial tests a combination of chemotherapy and immunotherapy before surgery for locally advanced bile duct cancer. The goal is to see if this approach can shrink the tumor enough to improve surgical outcomes.
This study tests a new way to treat a type of bile duct cancer (intrahepatic cholangiocarcinoma) using sound waves to destroy tumors. It also continues giving an immunotherapy drug called durvalumab. This combination may help control the cancer better and is for people whose cancer is not shrinking anymore after initial chemotherapy.
This trial tests whether pembrolizumab combined with gemcitabine and cisplatin given around the time of surgery can improve outcomes for people with high-risk, potentially operable intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help by strengthening the immune system while also treating the cancer with chemotherapy.
This trial tests a combination of a drug (durvalumab) that helps your immune system fight cancer, plus a special heat treatment applied inside the bile duct. It is for people with bile duct cancer that cannot be removed by surgery and who need a stent to open the bile duct.
Hear when a new Resectable Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.